May 07, 2026
A California federal judge has issued final judgments against a pharmaceutical company, its CEO and an affiliate on claims from the U.S. Securities and Exchange Commission that they defrauded investors of $6.6 million, hitting them with more than $2 million in damages and civil penalties.
November 25, 2025
A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.
October 23, 2025
The U.S. Securities and Exchange Commission has "unwittingly" taken the side of a former partner with a terminated licensing agreement, a pharmaceutical CEO told a California federal court this week, asking for summary judgment on the SEC's core claims that he defrauded investors.
October 03, 2022
The U.S. Securities and Exchange Commission is going after a pair of pharmaceutical companies that it says lied to potential investors about having exclusive rights to a method for taking CBD under the tongue in order to collect $6.6 million.